Guide to Interpreting Results
AlloSure® Kidney
Combining multiple thresholds and relative change value to add risk context
Interpretation Guide: AlloSure Kidney
Interpretive guide with a report walkthrough, trend views, and key report fields for review.
HeartCare®
A personalized risk report combining immune activation and graft injury
Interpretation Guide: HeartCare
Interpretive guide to the HeartCare report, including AlloMap and AlloSure Heart results and longitudinal graphs.
AlloSure® Lung
Combining multiple thresholds to add context for potential graft injury
Results notifications
Enroll in automated email notifications and select the frequency of receipt.
Questions about reports or results interpretation?
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on their education, clinical expertise, current guidelines, and assessment of the patient.
Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221- 2232.
Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. Am J Transplant. 2020;20(9):2491-2498.
Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med. 2017;2(3):309-321.
Khush K, Hall S, Kao A, et al. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: outcomes from the Surveillance HeartCare Outcomes Registry. J Heart Lung Transplant. 2024;43(9):1409-1421.
Keller MB, Newman D, Alnababteh M, et al. Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease. J Heart Lung Transplant. 2024;43(9):1374-1382.
Trindade AJ, Chapin KC, Gray JN, et al. Relative change in donor-derived cell-free DNA is superior to absolute values for diagnosis of acute lung allograft dysfunction. Transplant Direct. 2023;9(6):e1487.
Sayah D, Weigt SS, Ramsey A, Ardehali A, Golden J, Ross DJ. Plasma donor-derived cell-free DNA levels are increased during acute cellular rejection after lung transplant: pilot data. Transplant Direct. 2020;6(10):e608.